Cantor Fitzgerald (pre-mkt) reit'd $EYPT Overweight, says "there's nothing here that makes us less positive on the DME data/opportunity - if anything, it gives us higher confidence in the POS for a less clinically risky non-inferiority pivotal program:" $OCUL $REGN $SRZN $XBI TD Cowen reiterated $EYPT Buy-$20, says the 24-week benefit should still be enough to achieve Phase III success—and if the Phase III is successful with Q6M dosing, DME is a blockbuster opportunity that is not far off from wet AMD:
Cantor and Cowan still positive on EYPT . From a Quick Look at their trial ...small numbers and one patient that appeared to drop out then was " rescued " may have skewed results . OCUL tho IMHO is further ahead , has a P 3 readout in Q4 with 1 fully enrolled P 3 trial and a second recruiting , their previous trials indicated benefit in DME and they have plenty of cash . Some think they have the stronger drug They also will have first mover advantage JMO Kiwi
Market Data 
Markets 
AI
